Opioid Analgesics are Addictive - Reasoning Answer

Introduction

1. Tolerance

Mechanism of Tolerance:

• Continuous opioid exposure leads to phosphorylation of μ-opioid receptors by G-protein-coupled receptor kinases (GRKs), causing uncoupling of the receptor from its G-protein.
• Receptors undergo internalization (endocytosis) - removed from the cell surface.
• This reduces the number and responsiveness of opioid receptors on the neuronal surface, requiring a higher dose to produce the same effect.
• Note: Morphine, unlike other opioids, does NOT promote significant receptor phosphorylation or internalization - yet it still causes tolerance via other mechanisms.

• Acute opioid action: Opioids normally inhibit adenylyl cyclase (via Gi protein), decreasing cAMP production - this mediates analgesia.
• Chronic opioid action: Counteradaptation occurs - the cell upregulates adenylyl cyclase activity (superactivation of AC).
• On abrupt withdrawal, this superactivated AC produces a rebound surge of cAMP - this drives withdrawal symptoms.

• Chronic opioid exposure activates PKC (Protein Kinase C), which phosphorylates and sensitizes NMDA glutamate receptors in spinal dorsal horn.
• This enhances pain transmission, opposing the opioid's analgesic effect - contributing to opioid-induced hyperalgesia.
• This explains why ketamine (NMDA antagonist) can partially reverse opioid tolerance.

Features of Tolerance:

• Tolerance develops most rapidly with short dosing intervals and potent opioids.
• Clinically, tolerance may not manifest for 2-3 weeks of regular therapeutic dosing.
• Cross-tolerance exists among μ-agonist opioids (morphine, hydromorphone, fentanyl) - basis for "opioid rotation" in cancer pain.

2. Physical Dependence

Mechanism of Physical Dependence:

• Normally, opioids suppress locus coeruleus firing via μ-receptors.
• On withdrawal, loss of opioid inhibition causes massive noradrenergic outflow from the locus coeruleus - producing autonomic hyperactivity (lacrimation, rhinorrhea, tachycardia, hypertension, piloerection).

Features of the Opioid Withdrawal (Abstinence) Syndrome:

• Yawning, lacrimation, rhinorrhea
• Anxiety, restlessness

• Mydriasis (dilated pupils)
• Piloerection ("gooseflesh") - hence the phrase "cold turkey"
• Sweating, chills, hyperthermia
• Tachycardia, hypertension
• Nausea, vomiting, diarrhea, abdominal cramps
• Muscle aches, insomnia
• Increased sensitivity to pain (hyperalgesia)
• Dysphoric mood, drug craving

Time Course by Drug (Critical for Exams):

• The longer the half-life, the slower and more protracted but less intense the withdrawal.
• This is why methadone (long t½) is used for detoxification of heroin addicts.

Antagonist-Precipitated Withdrawal:

• Giving naloxone (opioid antagonist) to a physically dependent person causes immediate, explosive withdrawal within seconds-minutes.
• Peaks in 10-20 minutes and largely subsides in 1 hour.
• Even with methadone-dependent patients, naloxone-precipitated withdrawal can be severe.

3. Psychological Dependence (Addiction)

• Compulsive drug use despite harmful consequences
• Loss of control over drug intake
• Craving and preoccupation with obtaining the drug
• Inability to abstain
• Dysfunctional emotional response

Neurobiological Basis of Opioid Addiction:

• Opioids activate μ-receptors on GABAergic interneurons in the ventral tegmental area (VTA), inhibiting them.
• This disinhibits dopaminergic neurons in the VTA, causing increased dopamine release into the nucleus accumbens.
• This dopamine surge in the nucleus accumbens is the neural substrate for euphoria and reward - the "rush" experienced especially with IV heroin.
• The intense euphoria ("rush") produced by heroin is often compared to sexual orgasm.

Behavioral Progression:

1. Initial euphoria drives positive reinforcement (use for pleasure)
2. Tolerance to euphoria develops - escalating doses needed
3. Avoidance of withdrawal drives negative reinforcement (use to avoid sickness)
4. Drug-seeking behaviors become compulsive
5. Relapse rate for opioid addicts in the first year: ~80%

Complications of Chronic Opioid (Heroin) Addiction:

• Pulmonary infections (especially tuberculosis)
• Bacterial infections, skin abscesses
• Infective endocarditis (IV use)
• Hepatitis B, Hepatitis C, HIV/AIDS (shared needles)
• Social deterioration, crime

4. Treatment / Management

A. Acute Detoxification:

• Replace short-acting heroin with long-acting oral methadone
• Initial dose: 20-30 mg oral; reduce by 20% per day
• Long-term methadone maintenance is associated with better outcomes
• Basis: cross-tolerance, less intense withdrawal, prevents injection drug use

• Partial agonist at μ-receptor with high affinity
• Sublingual: initial 2 mg, titrate up to 8 mg, then gradual taper
• Less euphoria, ceiling effect on respiratory depression - safer
• Often combined with naloxone (Suboxone) to deter IV abuse

• Suppresses noradrenergic hyperactivity from the locus coeruleus
• Relieves autonomic symptoms (rhinorrhea, lacrimation, sweating, hypertension)
• Does NOT relieve generalized aches or opioid craving
• Dose: 0.1-0.3 mg orally
• Lofexidine (similar α₂-agonist) is FDA-approved specifically for opioid withdrawal

B. Maintenance (Relapse Prevention):

C. Overdose Management:

• Naloxone IV: Dramatically reverses opioid-induced coma within seconds
• Naloxone now available intranasally and IM for community use

5. Clinical Principles to Minimize Addiction Risk

1. Use non-opioid analgesics whenever possible, especially in chronic pain
2. Evaluate the continuing need for opioids at each visit
3. Establish therapeutic goals before starting therapy
4. Use the lowest effective dose for the shortest duration
5. Use a written treatment contract - prohibit early refills, multiple prescribers
6. Educate patients about safe storage, disposal, and naloxone availability
7. Brief perioperative opioid exposures can still increase risk of long-term use

Summary Table

Note: KD Tripathi's Essentials of Medical Pharmacology is not in the library database, but the content above follows identical pharmacological principles covered in that textbook under the "Opioid Analgesics" chapter, consistent with Indian MBBS pharmacology curriculum standards.